Trials / NCT02609165
Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
Completed Phase 2 Drug / neuroprotection
- Sponsor
- Ospedale San Raffaele
- Treatment
- rhNGF 180 µg/ml eye drops solution; vehicle eye drops
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Cystoid Macular Edema
- Ages
- 18 Years to no upper limit
- Enrollment
- 45 participants
- Started
- 2015-05
- Main results expected
- 2017-02
- Results posted
- Not yet
- Record last updated
- 2017-09-06
What the study is testing
This study aims at investigating the therapeutic potential of recombinant human Nerve Growth Factor ( rhNGF ) eye drops treatment in patients with Retinitis Pigmentosa (RP) associated with cystoid macular edema (CME) in a phase II, randomized, double-masked, controlled clinical trial.
Where it runs
Italy (2)
- Ospedale San Raffaele, Milan
- Ospedale Sacco, Milan